Kintor Pharmaceutical Limited, a biopharmaceutical company, engages in the research and development of drugs for the treatment of various cancers and other androgen receptor (AR) - related diseases in China, the United States, and Taiwan. More Details
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Kintor Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 9939 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: 9939's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
7 Day Return
1 Year Return
Return vs Industry: 9939 exceeded the Hong Kong Biotechs industry which returned 42.8% over the past year.
Return vs Market: 9939 exceeded the Hong Kong Market which returned 21.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Kintor Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Is Kintor Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 9939 (HK$51.5) is trading above our estimate of fair value (HK$36.34)
Significantly Below Fair Value: 9939 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 9939 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.
PE vs Market: 9939 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 9939's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 9939 is overvalued based on its PB Ratio (10.4x) compared to the HK Biotechs industry average (4.1x).
How is Kintor Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9939 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: 9939 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 9939's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if 9939's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 9939's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9939's Return on Equity is forecast to be low in 3 years time (7.2%).
How has Kintor Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 9939 is currently unprofitable.
Growing Profit Margin: 9939 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 9939 is unprofitable, and losses have increased over the past 5 years at a rate of 53% per year.
Accelerating Growth: Unable to compare 9939's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9939 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (43.1%).
Return on Equity
High ROE: 9939 has a negative Return on Equity (-33.71%), as it is currently unprofitable.
How is Kintor Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 9939's short term assets (CN¥1.4B) exceed its short term liabilities (CN¥169.3M).
Long Term Liabilities: 9939's short term assets (CN¥1.4B) exceed its long term liabilities (CN¥174.2M).
Debt to Equity History and Analysis
Debt Level: 9939's debt to equity ratio (14.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 9939's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9939 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 9939 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Kintor Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 9939's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 9939's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 9939's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 9939's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 9939's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Youzhi Tong (59 yo)
Dr. Youzhi Tong is the Chairman of the Board and Chief Executive Officer of Kintor Pharmaceutical Ltd and has been its Executive Director since May 16, 2018. Dr. Tong is primarily responsible for the overa...
Experienced Management: 9939's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Experienced Board: 9939's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 9939 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.
Kintor Pharmaceutical Limited's company bio, employee growth, exchange listings and data sources
- Name: Kintor Pharmaceutical Limited
- Ticker: 9939
- Exchange: SEHK
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$19.961b
- Shares outstanding: 387.59m
- Website: https://www.kintor.com.cn
Number of Employees
- Kintor Pharmaceutical Limited
- No. 20 Songbei Road
- Suzhou Industrial Park
- Jiangsu Province
Kintor Pharmaceutical Limited, a biopharmaceutical company, engages in the research and development of drugs for the treatment of various cancers and other androgen receptor (AR) - related diseases in Chin...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/17 16:37|
|End of Day Share Price||2021/06/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.